GALDERMA GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.83 CHF | -0.30% |
|
+0.99% | 0.00% |
| 06-19 | Global markets live: Vodafone, Bayer, Apple, Microsoft, Qualcomm... |  |
| 06-19 | Galderma Secures License for Injectable Aesthetic in Sweden | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 20,253 | - | - |
| Enterprise Value (EV) 1 | 22,605 | 22,060 | 21,358 |
| P/E ratio | 102 x | 40.9 x | 26.5 x |
| Yield | 0.04% | 0.33% | 0.57% |
| Capitalization / Revenue | 4.57 x | 4.07 x | 3.57 x |
| EV / Revenue | 5.1 x | 4.43 x | 3.76 x |
| EV / EBITDA | 22 x | 19 x | 15 x |
| EV / FCF | 314 x | 48.5 x | 31.7 x |
| FCF Yield | 0.32% | 2.06% | 3.16% |
| Price to Book | 2.61 x | 2.46 x | 2.29 x |
| Nbr of stocks (in thousands) | 237,898 | - | - |
| Reference price 2 | 85.13 | 85.13 | 85.13 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net sales 1 | 4,436 | 4,975 | 5,674 |
| EBITDA 1 | 1,028 | 1,161 | 1,425 |
| EBIT 1 | 864.2 | 1,022 | 1,307 |
| Operating Margin | 19.48% | 20.55% | 23.03% |
| Earnings before Tax (EBT) 1 | 297 | 612.5 | 943 |
| Net income 1 | 208.8 | 470.5 | 749 |
| Net margin | 4.71% | 9.46% | 13.2% |
| EPS 2 | 0.8355 | 2.083 | 3.211 |
| Free Cash Flow 1 | 72 | 455 | 674 |
| FCF margin | 1.62% | 9.15% | 11.88% |
| FCF Conversion (EBITDA) | 7% | 39.2% | 47.28% |
| FCF Conversion (Net income) | 34.48% | 96.71% | 89.99% |
| Dividend per Share 2 | 0.0337 | 0.2771 | 0.4849 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Net Debt 1 | 2,352 | 1,807 | 1,105 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | 2.288 x | 1.557 x | 0.7753 x |
| Free Cash Flow 1 | 72 | 455 | 674 |
| ROE (net income / shareholders' equity) | 6.84% | 8.55% | 10.6% |
| ROA (Net income/ Total Assets) | - | - | - |
| Assets 1 | - | - | - |
| Book Value Per Share 2 | 32.60 | 34.60 | 37.20 |
| Cash Flow per Share 2 | 32.80 | 18.80 | 4.240 |
| Capex 1 | 246 | 167 | 189 |
| Capex / Sales | 5.54% | 3.35% | 3.33% |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
85.13
USD
Average target price
86.24
USD
Spread / Average Target
+1.29%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 20.25B | |
| -1.78% | 254B | |
| +15.57% | 19.6B | |
| +11.59% | 11.69B | |
| -20.53% | 8.52B | |
| +19.17% | 7.61B | |
| +8.70% | 5.87B | |
| +3.07% | 3.87B | |
| -11.78% | 3.84B | |
| -22.07% | 3.59B |
- Stock Market
- Equities
- GALD Stock
- Financials Galderma Group AG
